Welcome to our dedicated page for ImageneBio SEC filings (Ticker: IMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ImageneBio, Inc. (neBio, Inc., Nasdaq: IMA) SEC filings page on Stock Titan aggregates the company’s U.S. regulatory disclosures, giving investors direct access to official information about this clinical-stage biotechnology issuer. neBio focuses on therapeutics for immunological, autoimmune, and inflammatory diseases, and its filings provide context on the development of its lead asset, -007, an investigational non-depleting anti-OX40 monoclonal antibody.
Through this page, users can review current reports on Form 8-K that document material events such as the completion and subsequent amendment of the merger between Inmagene Biopharmaceuticals and Ikena Oncology, Inc., changes in executive officers and directors, entry into or modification of material agreements, and the announcement of quarterly financial results. These filings also confirm that neBio’s common stock, with a par value of $0.001 per share, is registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Capital Market under the symbol IMA.
Investors can also locate neBio’s registration statement on Form S-1, which contains detailed descriptions of the company’s business, risk factors, and financial statements, including discussion of how historical financial data were adjusted to reflect the recapitalization associated with the merger. As the company advances -007 through clinical development, periodic and current reports provide additional insight into research and development spending, corporate structure, and key risk disclosures.
Stock Titan enhances these filings with AI-powered summaries that explain the significance of each document in accessible language. Users can quickly understand the main points of lengthy reports while retaining the option to open the full SEC filing text for deeper review, helping them follow IMA’s regulatory and corporate history with less manual effort.
ImageneBio, Inc. is holding a virtual 2026 Annual Meeting on June 16, 2026, for stockholders of record as of April 28, 2026. Stockholders will vote on electing two Class II directors, ratifying PricewaterhouseCoopers LLP as auditor for 2026, and approving an amended 2025 Equity Incentive Plan.
The equity plan amendment would add 850,000 shares to the plan and revise its evergreen formula to factor in shares issuable upon conversion of preferred stock and cash exercise of prefunded warrants. As of April 28, 2026, 11,279,130 shares of common stock were outstanding, and equity awards included 1,187,218 options and 652,517 restricted stock units.
The proxy describes ImageneBio’s post‑merger governance structure, with a classified board, a non‑executive chair, a lead independent director, fully independent key committees, and policies covering risk oversight, insider trading, hedging, and director independence. It also details audit fees and confirms prior auditor transition from Ernst & Young LLP to PricewaterhouseCoopers LLP.
OrbiMed Advisors LLC and affiliated funds filed Amendment No. 6 to their Schedule 13D on ImageneBio, Inc. common stock. The filing reflects purchases of pre-funded warrants in the company’s 2026 private placement (2026 PIPE) and updates OrbiMed’s beneficial ownership.
OrbiMed now reports beneficial ownership of 1,495,045 Shares, including 721,292 Shares underlying presently exercisable Pre-Funded Warrants, representing 13.1% of ImageneBio’s 11,375,573 outstanding Shares. OrbiMed Private Investments VI, LP holds 1,089,665 Shares (including 336,603 Pre-Funded Warrants) and OrbiMed Genesis Master Fund, L.P. holds 405,380 Shares (including 384,689 Pre-Funded Warrants). A separate client, Worldwide Healthcare Trust PLC, holds 135,516 Shares. The 2026 PIPE Pre-Funded Warrants are priced at $5.199 each and include a 19.99% ownership blocker.
ImageneBio (Common Stock) is reported as having an aggregate of 1,176,472 shares beneficially owned by Trails Edge entities and Ortav Yehudai as of April 14, 2026. That holding comprises 54,253 shares held directly and 1,122,219 shares issuable upon pre-funded warrants, and is stated as 9.9% of the class based on 10,654,281 shares outstanding as of March 2, 2026.
Omega Fund VI and related reporting persons have disclosed a significant ownership position in ImageneBio, Inc. common stock. They report beneficial ownership of 936,222 shares, including 480,861 shares underlying pre-funded warrants held by Omega Fund, representing 8.4% of the company’s common stock.
The stake was built through ImageneBio’s (formerly Ikena Oncology) IPO, a 2025 PIPE financing and a 2026 PIPE financing. In 2026, Omega Fund bought pre-funded warrants for 480,861 shares at $5.199 per warrant share for total consideration of $2,499,996, as part of a broader $30 million pre-funded warrant issuance.
The warrants have a $0.001 exercise price, are exercisable at any time and do not expire, but contain a beneficial ownership limitation capped at 19.99%. The reporting persons describe the holding as an investment and indicate they may discuss strategic, governance, or transactional matters with ImageneBio’s board and other stockholders while reserving flexibility to increase or reduce their position.
ImageneBio, Inc. principal accounting officer Robert B. Lally filed an initial statement of beneficial ownership, reporting his equity interests in the company. He holds 58,778 shares of common stock, including 56,940 restricted stock units, plus an employee stock option for 25,410 shares at $6.20 per share expiring on March 15, 2036.
ImageneBio, Inc. director Su Wei-guo has filed an insider ownership report showing no reportable transactions or derivative positions. The filing’s transaction summary lists zero buys, zero sells, zero exercises, and no gifts, tax withholdings, or restructurings, indicating a baseline disclosure without trading activity.
ImageneBio director–affiliated investment funds made a sizable indirect purchase of pre-funded warrants. On the April 14, 2026 closing of a private placement, OrbiMed Private Investments VI, LP and OrbiMed Genesis Master Fund, L.P. acquired pre-funded warrants to buy a total of 721,292 shares of ImageneBio common stock at a price of $5.199 per warrant. These pre-funded warrants are exercisable at $0.001 per share and include a 19.99% beneficial ownership blocker. After the transactions, the OrbiMed funds also indirectly held 753,062 and 20,691 shares of common stock, and all entities, including director Bonita P. David, disclaim beneficial ownership beyond any pecuniary interest.
ImageneBio, Inc. reported that funds affiliated with OrbiMed purchased pre-funded warrants in a private placement. OrbiMed-related vehicles acquired pre-funded warrants to buy up to 721,292 shares of common stock at a price of $5.199 per warrant, with an exercise price of $0.001 per share.
The pre-funded warrants are exercisable at any time after issuance, subject to a 19.99% beneficial ownership blocker, and expire once fully exercised. The securities are held of record by OrbiMed Private Investments VI, LP and OrbiMed Genesis Master Fund, L.P., with OrbiMed entities and their principals disclaiming beneficial ownership beyond any pecuniary interest.
ImageneBio, Inc. files a prospectus supplement registering 2,508,337 shares of Common Stock for resale by identified selling stockholders. The supplement incorporates a Form 8-K disclosing a related private placement of pre-funded warrants to purchase up to 5,770,335 Warrant Shares at $5.199 per Warrant Share for gross proceeds of approximately $30 million, with the pre-funded warrants exercisable at $0.001 per share and subject to beneficial ownership limits (including 19.99%). The registration covers resale by selling holders; proceeds from those resales will go to the selling holders, not the company.